AbbVie Inc. $ABBV Shares Sold by Trust Co. of Vermont

Trust Co. of Vermont reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 168,625 shares of the company’s stock after selling 5,899 shares during the quarter. AbbVie accounts for 1.6% of Trust Co. of Vermont’s portfolio, making the stock its 12th largest position. Trust Co. of Vermont’s holdings in AbbVie were worth $38,529,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. PICTET BANK & TRUST Ltd raised its stake in shares of AbbVie by 28.2% in the 4th quarter. PICTET BANK & TRUST Ltd now owns 8,888 shares of the company’s stock valued at $2,031,000 after acquiring an additional 1,956 shares during the period. Oldfather Financial Services LLC boosted its position in AbbVie by 21.5% during the 4th quarter. Oldfather Financial Services LLC now owns 1,856 shares of the company’s stock worth $424,000 after purchasing an additional 328 shares during the period. Cyr Financial Inc. purchased a new stake in AbbVie during the 4th quarter worth $1,005,000. Banque Pictet & Cie SA increased its holdings in AbbVie by 16.5% in the 4th quarter. Banque Pictet & Cie SA now owns 388,924 shares of the company’s stock valued at $88,865,000 after purchasing an additional 54,953 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC raised its position in AbbVie by 3.1% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 13,507 shares of the company’s stock valued at $3,086,000 after purchasing an additional 407 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on ABBV shares. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Evercore dropped their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. UBS Group reduced their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Royal Bank Of Canada began coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Federal tax-law effects: Analysts and reports show U.S. corporate cash taxes fell roughly $65B after recent tax changes, a trend benefiting large pharma cash flow and near-term free cash flow for companies like AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Positive Sentiment: Allergan Aesthetics promotion: AbbVie’s aesthetics unit is running its fourth annual CoolMonth promotion (CoolSculpting offers), which can modestly boost procedure volumes and near-term aesthetics revenue. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Neutral Sentiment: Earnings schedule: AbbVie set its Q1 2026 results release and conference call for April 29 (pre-market), a scheduled event that will be the next major catalyst for stock direction. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Mixed intraday moves: Recent headlines show short-term intraday swings (some sessions with gains, others with underperformance versus the market), indicating investor attention is currently fragmented between fundamentals and newsflow. AbbVie Inc. stock rises Tuesday, still underperforms market AbbVie (ABBV) Gains As Market Dips: What You Should Know
• Negative Sentiment: Litigation tied to Cerevel/AbbVie deal: A court ordered Pfizer and Bain to litigate a suit by Cerevel investors over the AbbVie transaction, creating deal-related legal uncertainty and potential distraction or liabilities. That legal cloud can pressure sentiment around transactions and M&A strategy. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: Analyst commentary flags likely 2026 revenue pressure in AbbVie’s oncology franchise — pricing pressure on Imbruvica and a near-term dip in legacy oncology sales could offset growth from newer oncology assets. This is a direct revenue-risk item investors care about for 2026 guidance. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?

AbbVie Price Performance

Shares of AbbVie stock opened at $214.72 on Thursday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market capitalization of $379.66 billion, a PE ratio of 90.98, a P/E/G ratio of 0.76 and a beta of 0.38. The business has a 50-day moving average of $221.98 and a 200-day moving average of $224.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.